04 Feb 2020 --- Ingredients company Amyris has entered into definitive securities purchase agreements in a US$112 million recapitalization anchored by Foris Ventures. Foris exercized existing warrants to convert approximately US$70 million of the biotech company’s debt into common stock, valued at around US$2.87 per share. In addition to the significant debt reduction, the company raised US$42 million in new financing led by Foris and several other long-term holders.